Upgrade to SI Premium - Free Trial

RBC Capital Maintains Sector Perform Rating and $22 PT on Valent Pharmaceuticals (VRX) Following Q4 Results, 2017 'Guidance Lower than Street'

February 28, 2017 7:42 AM
RBC Capital Markets analyst Douglas Miehm reiterates Sector Perform rating and $22 price target on Valeant Pharmaceuticals, as the company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles